Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor II and Factor V with Risk of Inhibitor Development in Patients with Severe Hemophilia A
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: About one-fourth of patients with hemophilia A (HA) develop alloantibodies against factor (F) VIII, as the main treatment challenge. Here, we assessed the relationship between interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α), FII and FV polymorphisms and risk of inhibitor formation in patients with severe HA.
METHODS: We divided 39 patients with severe HA in two groups of case (n: 19) and control (n: 20). Genotyping was performed by multiplex amplification tetra arms refractory mutation systempolymerase chain reaction (ARMS-PCR) and PCR-restriction fragment-length polymorphism (PCR-RFLP).
RESULTS: TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor development in codominant and dominant inheritance pattern. Moreover, TNFα rs1800629 A allele, decrease the risk of inhibitor formation, while IL10 rs1800896 A>G, FV rs6025 G>A, and FII rs1799963 G>A polymorphisms were not associated with risk of inhibitor development.
CONCLUSION: It seems that TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor formation in Iranian patients with HA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Cardiovascular & hematological disorders drug targets - 19(2019), 3 vom: 22., Seite 228-232 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soori, Shahrzad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
130068-27-8 |
|---|
| Anmerkungen: |
Date Completed 04.08.2020 Date Revised 04.08.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871529X19666190206152315 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM293540233 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM293540233 | ||
| 003 | DE-627 | ||
| 005 | 20231225075534.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871529X19666190206152315 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0978.xml |
| 035 | |a (DE-627)NLM293540233 | ||
| 035 | |a (NLM)30727925 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soori, Shahrzad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor II and Factor V with Risk of Inhibitor Development in Patients with Severe Hemophilia A |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.08.2020 | ||
| 500 | |a Date Revised 04.08.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: About one-fourth of patients with hemophilia A (HA) develop alloantibodies against factor (F) VIII, as the main treatment challenge. Here, we assessed the relationship between interleukin-10 (IL-10), tumor necrosis factor alpha (TNF-α), FII and FV polymorphisms and risk of inhibitor formation in patients with severe HA | ||
| 520 | |a METHODS: We divided 39 patients with severe HA in two groups of case (n: 19) and control (n: 20). Genotyping was performed by multiplex amplification tetra arms refractory mutation systempolymerase chain reaction (ARMS-PCR) and PCR-restriction fragment-length polymorphism (PCR-RFLP) | ||
| 520 | |a RESULTS: TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor development in codominant and dominant inheritance pattern. Moreover, TNFα rs1800629 A allele, decrease the risk of inhibitor formation, while IL10 rs1800896 A>G, FV rs6025 G>A, and FII rs1799963 G>A polymorphisms were not associated with risk of inhibitor development | ||
| 520 | |a CONCLUSION: It seems that TNFα rs1800629 G>A polymorphism decreased the risk of inhibitor formation in Iranian patients with HA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hemophilia A | |
| 650 | 4 | |a IL10 | |
| 650 | 4 | |a TNF a | |
| 650 | 4 | |a factor II | |
| 650 | 4 | |a factor V | |
| 650 | 4 | |a inhibitor | |
| 650 | 4 | |a polymorphism. | |
| 650 | 7 | |a IL10 protein, human |2 NLM | |
| 650 | 7 | |a Isoantibodies |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-10 |2 NLM | |
| 650 | 7 | |a 130068-27-8 |2 NLM | |
| 650 | 7 | |a Factor V |2 NLM | |
| 650 | 7 | |a 9001-24-5 |2 NLM | |
| 650 | 7 | |a Prothrombin |2 NLM | |
| 650 | 7 | |a 9001-26-7 |2 NLM | |
| 700 | 1 | |a Dadashizadeh, Ghazaleh |e verfasserin |4 aut | |
| 700 | 1 | |a Dorgalaleh, Akbar |e verfasserin |4 aut | |
| 700 | 1 | |a Tabibian, Shadi |e verfasserin |4 aut | |
| 700 | 1 | |a Keramati, Mohammad R |e verfasserin |4 aut | |
| 700 | 1 | |a Alizadeh, Shaban |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Maryam S |e verfasserin |4 aut | |
| 700 | 1 | |a Zaker, Farhad |e verfasserin |4 aut | |
| 700 | 1 | |a Shams, Mahmood |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular & hematological disorders drug targets |d 2006 |g 19(2019), 3 vom: 22., Seite 228-232 |w (DE-627)NLM163039259 |x 2212-4063 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:3 |g day:22 |g pages:228-232 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871529X19666190206152315 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 3 |b 22 |h 228-232 | ||